Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization - Scorecard - MDSpire

Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization

  • By

  • Ettore di Gaeta

  • Makoto Taninokuchi Tomassoni

  • Francesca Calabrese

  • Giovanni Matassa

  • Annarita Savi

  • Carla Canevari

  • Patrizia Magnani

  • Giovanna Pepe

  • Stephanie Steidler

  • Francesca Ratti

  • Federica Cipriani

  • Margherita Rimini

  • Andrea Casadei-Gardini

  • Lorenzo Braccischi

  • Maria Adriana Cocozza

  • Lidia Strigari

  • Giuseppe Della Gala

  • Arber Golemi

  • Elisa Lodi Rizzini

  • Stefano Fanti

  • Matteo Cescon

  • Matteo Serenari

  • Fabio Piscaglia

  • Maria Cristina Morelli

  • Arturo Chiti

  • Cristina Mosconi

  • Francesco De Cobelli

  • April 28, 2026

  • 0 min

Share

Clinical Scorecard: Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization

At a Glance

CategoryDetail
ConditionHepatocellular carcinoma (HCC)
Key MechanismsTransarterial radioembolization (TARE) using Yttrium-90 (90Y) resin microspheres for targeted tumor treatment.
Target PopulationPatients with early to advanced-stage HCC not suitable for surgical resection or liver transplantation.
Care SettingMultidisciplinary tumor boards in specialized hospitals.

Key Highlights

  • TARE with 90Y resin microspheres shows improved overall survival and objective response rates.
  • Personalized dosimetry is crucial for optimizing treatment outcomes.
  • Radiological response assessed at 3 months post-TARE is a reliable indicator of treatment efficacy.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of HCC can be made radiologically or pathologically.

Management

  • TARE with 90Y is indicated for disease control across all BCLC stages.

Monitoring & Follow-up

  • Follow-up imaging and clinical data collection are essential for assessing treatment response.

Risks

  • Careful monitoring of liver and lung doses is necessary to minimize treatment-related complications.

Patient & Prescribing Data

64 patients diagnosed with HCC treated with TARE.

Personalized dosimetry aims for tumor absorbed doses > 120 Gy while limiting normal liver and lung doses.

Clinical Best Practices

  • Utilize planning angiography and SPECT/CT for accurate dosimetry and treatment planning.
  • Adhere to established guidelines for dose limits to normal liver and lung tissue.

References

Original Source(s)

Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization

  • by Ettore di Gaeta, Makoto Taninokuchi Tomassoni, Francesca Calabrese, Giovanni Matassa, Annarita Savi, Carla Canevari, Patrizia Magnani, Giovanna Pepe, Stephanie Steidler, Francesca Ratti, Federica Cipriani, Margherita Rimini, Andrea Casadei-Gardini, Lorenzo Braccischi, Maria Adriana Cocozza, Lidia Strigari, Giuseppe Della Gala, Arber Golemi, Elisa Lodi Rizzini, Stefano Fanti, Matteo Cescon, Matteo Serenari, Fabio Piscaglia, Maria Cristina Morelli, Arturo Chiti, Cristina Mosconi, Francesco De Cobelli

  • April 28, 2026

Related Content

Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy

Couinaud segment-aware deep learning on point clouds for major liver resection planning

Deep-Motion-Net: GNN-based volumetric liver shape reconstruction from single-view 2D projections